Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an
immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
Phase:
Phase 2
Details
Lead Sponsor:
Anelixis Therapeutics, Inc. Anelixis Therapeutics, LLC